Investor Relations

Latest Financial Results

Stock Information

Aurinia Pharmaceuticals Inc.
Nasdaq: AUPH Symbol
Price
Change
Volume
Day Range
52 Wk Range

Company Overview

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

view management team  view board of directors

Contact Information

Investor Relations

Aurinia@westwicke.com

Transfer Agent

Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
https://www.computershare.com

Media

Andrea Christopher
Director Corporate Communications
achristopher@auriniapharma.com